Stock of the Day

June 2, 2021

GoodRx (GDRX)

$3.49
-$0.04 (-1.1%)
Market Cap: $1.21B

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Today's Trend

GoodRx Holdings, Inc. (NASDAQ: GDRX) shares increased after the company’s second-quarter 2026 results and outlook signaled stronger-than-expected revenue performance and continued profitability.

  • GoodRx reported second-quarter revenue of $200.4 million, exceeding analysts’ $193.2 million consensus estimate. Adjusted net income reached $26.8 million, while adjusted EBITDA was $63.7 million, highlighting solid operating profitability. GoodRx Reports Second Quarter 2026 Results
  • The company raised or reiterated full-year 2026 revenue guidance of $790 million to $805 million, above the $775.7 million analyst consensus. The outlook likely improved investor expectations for growth in the second half of the year.
  • Management emphasized GoodRx’s technology platform and its ability to adapt as consumer healthcare needs and customer behavior change, supporting the company’s positioning in medication savings and digital healthcare. GoodRx and Oscar Health Tout Tech as Consumer Needs Change
  • Adjusted earnings were not the only focus of the quarter: GAAP EPS was $0.08, matching consensus, while the company’s revenue beat was the primary upside surprise. GoodRx Q2 2026 Earnings Call Transcript
  • Revenue declined 1.3% year over year, and EPS fell from $0.09 in the prior-year quarter to $0.08. These figures indicate that GoodRx still faces challenges returning to sustained top-line growth.
← Previous Stock of the DayNext Stock of the Day →

Recent News